Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients

Renal Failure

Volumn 33, Issue 3, 2011, Pages 373-375

  Loughnan, Alice ^a   Ali, Galil Rahman ^a   Abeygunasekara, Sumith C ^a  

^a BROOMFIELD HOSPITAL   (United Kingdom)

Author keywords

anemia; epoetin alfa; epoetin beta; Hemodialysis

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANEMIA; EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 79952677918     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.559675     Document Type: Article

References (13)

1. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kid-ney Dis. 2004;44(1):94-111. (Pubitemid 38880932)
2. Tompson C. UK renal registry 12th annual report (Decem-ber 2009): Chapter 1 summary of findings in the 2009 UK registry report. Nephron Clin Pract. 2010;115(Suppl. 1):1.
3. NICE. National Costing Report: Anaemia management in people with CKD 2006 Mid City Place, London: NICE (National Institute of Clinical Excellence), Available at: www.nice.org.uk/CG039. Accessed February 25, 2011.
4. Deicher R, Horl WH. Differentiating factors between erythro-poiesis- stimulating agents-A guide to selection for anaemia of chronic kidney disease. Drugs. 2004;64(5):499-509. (Pubitemid 38338727)
5. National Kidney Foundation. IV. NKF-K/DOQI Clinical prac-tice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis. 2001;37(Suppl 1):S182-S238.
6. Locatelli F, Aljama PA, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19:1-47.
7. Halstenson CE, Macres M, Katz SA, et al. Comparative phar-macokinetics and pharmacodynamics of epoetin-alfa and epo-etin-beta. Clin Pharmacol Ther. 1991;50(6):702-712.
8. Sorgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharm Ther. 2009;47(6):391-401.
9. Ifudu O, Cohen LS, Mayers JD, Joseph A, Delano BG, Friedman EA. Residual renal function modulates response to erythropoietin in chronic renal insufficiency. Dial Transplant. 2001;30(6):344-354. (Pubitemid 32510311)
10. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynam-ics of recombinant-human-erythropoietin in hemodialysis-patients. Br J Clin Pharmacol. 1992;34(6):499-508.
11. Lopez-Gomez JM, Perez-Flores I, Jofre R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state, and erythropoietin resistance. J Am Soc Nephrol. 2004;15(9)2494-2501. (Pubitemid 39159351)
12. Kaysen GA, Muller HG, Ding J, Chertow GM. Challenging the validity of the EPO index. Am J Kidney Dis. 2006; 47(1):157-166.
13. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condi-tion the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008; 111:S75-S81.